Bibliography
- KRAKAUER T, VILCEK J, OPPENHEIM JJ: Proinflammatory Cytokines. In: Fundamental Immunology Paul WE (Ed), Lippincott-Raven, Philadelphia, USA (1999):775–812.
- BAZZONI F, BEUTLER B: The tumor necrosis factor ligand and receptor families. N Engl. J. Med. (1996) 334:1717–1725.
- FELDMAN M: Anti-TNFa therapy of rheumatoid arthritis: what have we learned? Ann. Rev Immunol (2001) 19:163–196.
- MORELAND LW: Recent advances in anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis. Biodrugs (1999) 11:201–210.
- RICHARD-MICELI C, DOUGADOS M:Tumor necrosis factor-a blockers in rheumatoid arthritis. Biodrugs (2001) 15:251–259.
- KALDEN JR: Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. (2002) 4\(Supp1.2):34–40.
- KEATING GM, PERRY CM: Infliximab. An updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrugs (2002) 16:111–148.
- BODMER J-L, SCHNEIDER P, TSCHOPP, J: The molecular architecture of the TNF superfamily. TRENDS in Biochem. Sci. (2002) 27:19–26.
- •This review of the structural features demi/1g TNF ligands and their receptors includes http addresses for useful websites.
- MAC EWAN DJ: TNF receptor subtype signalling: differences and cellular consequences. Cellular Signalling (2002) 14:477–492.
- •Reviews current understanding of TNER1 and TNER2, their structural basis of signalling and associated adaptor protein, and cellular consequences with 412 references.
- STRATER J, MOLLER P: Expression and function of death receptors and their natural ligands in the intestine. Ann. NY Acad. Set. (2000) 915:162–170.
- TILG H: Cytokines and liver diseases. Can. Castroenterol (2001)15:661–668.
- HOFBAUER LC, HEUFELDER AE: Role of receptor activator of nuclear factor-1(B ligand and osteroprotegrin in bone cell biology.' MM. Med. (2001) 79:243–253.
- DUMONT FJ: BAFF et al: novel members of the TNF ligand and receptor families as therapeutic targets. Expert Opin. Ther. Patents (2002) 12:1351–1365.
- ••An excellent review of TNF ligand andreceptor family members associated with B cell immunity that summarises findings from over 200 manuscripts and patents.
- MADRY C, LAABI Y, CALLEBAUT I et al: The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int. Immunity (1998) 10:1693–1702.
- VON BOLOW G-U, BRAM RJ: NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science (1997) 278:138–141.
- •Structural and functional characterisation of the TNF receptor family member TACT.
- YU G, BOONE T, DELANEY J et a/.: APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunology(2000) 1:252–256.
- YAN M, WANG H et al: Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunology(2001) 2:638–643.
- THOMPSON KS, BIXLER SA, QIAN F et al.: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFE Science (2001) 293:2108–2111.
- •The BAFF-R locus is disrupted in A/SySnJ mice which display decreased numbers of peripheral blood B cells.
- BANCHEREAU J, BAZAN F, BLANCHARD D et al.: The CD40 antigens and its ligand. Ann. Rev Immunol (1994) 12:881–922.
- BRAMS P, BLACK A, PADLAN EA et al.: A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int. Immunopharmacol (2001) 1:277–294.
- DE VITA S, ZAJA F, SACCO S, DE CANDIA A, FANIN R, FERRACCIOLI G: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Evidence for a pathogenetic role of B cells. Arthritis Rheum. (2002) 46:2029–2033.
- WINKLER U, JENSEN M, MANZKE O, SCHULZ H, DIEHL V, ENGERT A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood (1999) 94:2217–2224.
- ISAACS JD: From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology (2001) 40:724–738.
- DUMONT FJ: IDEC-131. Curt: Opin. Invest. Drugs (2002) 3:725–734.